[A17-30] Ixekizumab (plaque psoriasis) - Addendum to Commission A17-07

Last updated 17.08.2017

Project no.:
A17-30

Commission:
Commission awarded on 11.07.2017 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Skin and hair

Indication/Intervention:

Adults with moderate to severe plaque psoriasis

Result of dossier assessment:

Indication of considerable added benefit now also for patients who are eligible for systemic and/or phototherapy

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Current document

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Federal Joint Committee (G-BA)

2017-08-17 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.